The purpose of this 3 year contract is to establish a cooperative system concerning Boehringer-Ingelheim’s newly developed antitumor drugs with the National Cancer Research Center so that clinical development in Japan can be undertaken early. Drug discovery using the seeds of the National Cancer Research Center it is not included in the partnership.

Boehringer Ingelheim Japan news release, July 11, 2017